Therapeutic intervention of this aberrantly regulated pathway using BCL-2 inhibitor venetoclax (VEN; ABT-199) thus seems beneficial and demonstrated clinical efficacy in CLL [6, 7] and AML patients [8, 9]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.